CSL有限公司将开展临床试验,验证下一代Horizon 2工艺生产的免疫球蛋白有效性与安全性

美股速递
Jul 29

CSL有限公司宣布,将启动一项临床试验工作,旨在确认其采用下一代Horizon 2工艺生产的免疫球蛋白的有效性和安全性。这一举措标志着公司在该领域的技术创新迈入关键验证阶段。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10